PortfoliosLab logoPortfoliosLab logo
ENTA vs. SOGP
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ENTA vs. SOGP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Enanta Pharmaceuticals, Inc. (ENTA) and Lizhi Inc (SOGP). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ENTA achieves a -24.54% return, which is significantly lower than SOGP's 3.93% return.


ENTA

1D
3.39%
1M
-15.18%
YTD
-24.54%
6M
-19.21%
1Y
60.59%
3Y*
-21.72%
5Y*
-24.07%
10Y*
-6.52%

SOGP

1D
-3.95%
1M
-24.95%
YTD
3.93%
6M
-7.95%
1Y
682.39%
3Y*
12.23%
5Y*
-28.51%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

ENTA vs. SOGP - Yearly Performance Comparison


2026 (YTD)202520242023202220212020
ENTA
Enanta Pharmaceuticals, Inc.
-24.54%174.26%-38.89%-79.77%-37.79%77.62%-28.13%
SOGP
Lizhi Inc
3.93%465.48%-20.80%-56.51%-65.95%-52.32%-64.82%

Correlation

The correlation between ENTA and SOGP is 0.09, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.09

Correlation (3Y)
Calculated over the trailing 3-year period

0.07

Correlation (5Y)
Calculated over the trailing 5-year period

0.14

Correlation (All Time)
Calculated using the full available price history since Jan 17, 2020

0.14

Fundamentals

Total Revenue (TTM)

ENTA:

$69.21M

SOGP:

CN¥2.07B

Gross Profit (TTM)

ENTA:

$33.44M

SOGP:

CN¥585.38M

EBITDA (TTM)

ENTA:

-$61.85M

SOGP:

-CN¥138.59M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ENTA vs. SOGP — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ENTA
ENTA Risk / Return Rank: 7272
Overall Rank
ENTA Sharpe Ratio Rank: 6161
Sharpe Ratio Rank
ENTA Sortino Ratio Rank: 7878
Sortino Ratio Rank
ENTA Omega Ratio Rank: 7777
Omega Ratio Rank
ENTA Calmar Ratio Rank: 7373
Calmar Ratio Rank
ENTA Martin Ratio Rank: 7070
Martin Ratio Rank

SOGP
SOGP Risk / Return Rank: 9696
Overall Rank
SOGP Sharpe Ratio Rank: 9393
Sharpe Ratio Rank
SOGP Sortino Ratio Rank: 9999
Sortino Ratio Rank
SOGP Omega Ratio Rank: 9797
Omega Ratio Rank
SOGP Calmar Ratio Rank: 9797
Calmar Ratio Rank
SOGP Martin Ratio Rank: 9292
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ENTA vs. SOGP - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Enanta Pharmaceuticals, Inc. (ENTA) and Lizhi Inc (SOGP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


ENTASOGPDifference
Sharpe ratioReturn per unit of total volatility

-1.85

Sortino ratioReturn per unit of downside risk

-3.72

Omega ratioGain probability vs. loss probability

1.27

1.68

-0.42

Calmar ratioReturn relative to maximum drawdown

1.78

9.74

-7.97

Martin ratioReturn relative to average drawdown

3.36

13.60

-10.25

ENTA vs. SOGP - Sharpe Ratio Comparison

The current ENTA Sharpe Ratio is 0.56, which is lower than the SOGP Sharpe Ratio of 2.40. The chart below compares the historical Sharpe Ratios of ENTA and SOGP, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

ENTA vs. SOGP - Drawdown Comparison

The maximum ENTA drawdown since its inception was -96.63%, roughly equal to the maximum SOGP drawdown of -99.25%. Use the drawdown chart below to compare losses from any high point for ENTA and SOGP.


Loading charts...

Drawdown Indicators


ENTASOGPDifference

Max Drawdown

Largest peak-to-trough decline

-96.63%

-99.25%

+2.62%

Max Drawdown (1Y)

Largest decline over 1 year

-34.30%

-70.70%

+36.40%

Max Drawdown (3Y)

Largest decline over 3 years

-82.38%

-89.12%

+6.74%

Max Drawdown (5Y)

Largest decline over 5 years

-95.62%

-98.42%

+2.80%

Max Drawdown (10Y)

Largest decline over 10 years

-96.63%

Current Drawdown

Current decline from peak

-90.58%

-91.94%

+1.36%

Average Drawdown

Average peak-to-trough decline

-49.27%

-84.33%

+35.06%

Ulcer Index

Depth and duration of drawdowns from previous peaks

18.11%

50.53%

-32.42%

Volatility

ENTA vs. SOGP - Volatility Comparison

Enanta Pharmaceuticals, Inc. (ENTA) has a higher volatility of 13.67% compared to Lizhi Inc (SOGP) at 11.95%. This indicates that ENTA's price experiences larger fluctuations and is considered to be riskier than SOGP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


ENTASOGPDifference

Volatility (1M)

Calculated over the trailing 1-month period

13.67%

11.95%

+1.72%

Volatility (6M)

Calculated over the trailing 6-month period

35.48%

57.53%

-22.05%

Volatility (1Y)

Calculated over the trailing 1-year period

109.73%

286.72%

-176.99%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

73.36%

156.38%

-83.02%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

60.69%

160.50%

-99.81%

Dividends

ENTA vs. SOGP - Dividend Comparison

ENTA has not paid dividends to shareholders, while SOGP's dividend yield for the trailing twelve months is around 19.66%.


PositionTTM2025
ENTA
Enanta Pharmaceuticals, Inc.
0.00%0.00%
SOGP
Lizhi Inc
19.66%8.61%

Financials

ENTA vs. SOGP - Financials Comparison

This section allows you to compare key financial metrics between Enanta Pharmaceuticals, Inc. and Lizhi Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00100.00M200.00M300.00M400.00M500.00M600.00M20222023202420252026
17.16M
422.82M
(ENTA) Total Revenue
(SOGP) Total Revenue
Please note, different currencies. ENTA values in USD, SOGP values in CNY

Frequently Asked Questions


ENTA and SOGP have a correlation of 0.09, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ENTA has higher volatility (13.67%) compared to SOGP (11.95%). In terms of maximum drawdown, ENTA dropped -96.63% vs SOGP's -99.25%.

SOGP currently has the higher Sharpe Ratio (2.40 vs 0.56), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ENTA and SOGP

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer